Glatiramer acetate treatment negatively regulates type I interferon signaling

In the article “Glatiramer acetate treatment negatively regulates type I interferon signaling” by N. Molnarfi et al. (Neurol Neuroimmunol Neuroinflamm 2015;2:e179. DOI: 10.1212/NXI.0000000000000179), originally published on November 9, 2015, there is an error in the description of figure 2B. This figure shows IκBα degradation, not IκBα phosphorylation as originally described. In Methods (“Western blot”), the second sentence should read “Nitrocellulose membranes were probed (4°C, overnight) with antibodies against phospho-Akt1 (Ser473), phospho-JNK (Thr183/Tyr185), phospho-p38 MAP kinase (Thr180/Tyr182), IĸBɑ, glyceraldehyde-3-phosphate dehydrogenase (GAPDH), total STAT1, and total Akt1/2/3 (Cell Signaling Technology, Danvers, MA).” In figure 2, the label above panel B should read just “IĸBɑ” and the corresponding sentence in the legend should read “…and membranes were probed for IĸBɑ.” In the second paragraph under Results (“GA inhibits TRIF-dependent, but not MyD88-dependent, signaling”), the 13th sentence should read “As shown in figure 2B, GA exposure did not impair degradation of the inhibitor protein IĸBɑ following LPS treatment.” The authors regret this error.